Rhythm Biosciences (ASX: RHY) share price slumps amid ‘pivotal’ board changes

This healthcare company is developing a blood test to detect colorectal cancer
The post Rhythm Biosciences (ASX: RHY) share price slumps amid ‘pivotal’ board changes appeared first on The Motley Fool Australia. –

The Rhythm Biosciences Ltd (ASX: RHY) share price is in the red today after the company announced a board and management restructure.

At the time of writing, the cancer diagnostics company is trading down 4.26% at $1.76. This follows a stellar day in the market on Tuesday which saw the Rhythm Biosciences share price surge 11.21% to an intraday high of $2 before closing at $1.83.

What did Rhythm Biosciences announce today?  

In today’s release, the company announced significant changes to the board and management structure, effective immediately.

Non-executive chair Otto Buttula moves to executive chair, while CEO Glenn Gilbert joins the board as a managing director.

The promotion for Buttula will see his pay increase from $84,000 to $150,000, while Gilbert’s take-home salary will stay the same.    

Commenting on the changes, Buttula said:

The board has decided to make these changes at a pivotal time to leverage Glenn and my joint experience driving corporate and commercial scale-up activities. Glenn has already established a robust platform that has positioned Rhythm to continue maximising value for all stakeholders.

I view this executive function for the chair to be a short-term, but important role to provide further executive corporate support to the company as it enters several critical commercialization agreements across the globe.

What else is news at Rhythm Biosciences?

Investors appeared to welcome an announcement from the company yesterday which included an update on its ColoStat blood test for detecting colorectal cancer.  

The company said it had achieved a major regulatory milestone for the commercialisation of ColoStat, paving the way for commersialisation in global markets including Europe.

According to Rhythm Biosciences, Colostat will reduce health costs, sickness and deaths associated with colorectal cancer by increasing current screening rates.

Rhythm Biosciences share price snapshot

The Rhythm Biosciences share price has skyrocketed this year, up 187.7% in the past 12 months.

On Tuesday, the share price was in the green 7.4% at the close after the ColoStat regulatory milestone.

The post Rhythm Biosciences (ASX: RHY) share price slumps amid ‘pivotal’ board changes appeared first on The Motley Fool Australia.

Should you invest $1,000 in Rhythm Biosciences right now?

Before you consider Rhythm Biosciences, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Rhythm Biosciences wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

Rhythm Biosciences (ASX:RHY) share price rockets amid US$12bn market opportunity

These were the best performing ASX healthcare shares in October

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!